Loading…
Biotech selling small-molecule and gene-therapy drugs for rare genetic diseases, including spinal muscular atrophy and Duchenne muscular dystrophy.
Biotech selling small-molecule and gene-therapy drugs for rare genetic diseases, including spinal muscular atrophy and Duchenne muscular dystrophy.
Combines sales of its own rare-disease drugs, priced for very small patient groups and sold through specialty pharmacies, with royalties from Roche's Evrysdi, a spinal muscular atrophy drug it helped discover, which arrive without selling costs. It has sold part of that royalty stream to Royalty Pharma, and the rest helps fund its pipeline.
Moat: narrow (IP / patents, regulatory licence). Deep rare-neuromuscular-disease expertise and orphan exclusivity across a diversified genetic-disease portfolio.
Headquarters: Warren, New Jersey, United States · Founded: 1998 · Employees: 991
Size PTC Therapeutics (PTCT) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $5.47B, the 1123rd largest of 3,117 United States companies the cockpit tracks. Shares closed at $65.44 on 6 Nov 2026.
Performance Over six months the shares fell 11.2%, against -0.9% for the median peer and -1.1% for the United States market (cap-weighted) — 5th lowest of 19 in its peer set.
Growth Revenue fell 35.0% over the last twelve months (peer median +10.6%); the operating margin is 21.6% (peer median 15.6%).
Valuation It trades at 34.8× forward earnings against a peer median of 24.0× (4th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is -27 pp: the price already allows for a slowdown.
Short interest Short interest is 9.9% of the free float (15 Oct 2026).
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.16B | $1.73B | $807M | $938M | $699M |
| Revenue growth | — | +115% | -14% | +34% | — |
| Gross profit | $1.03B | $1.66B | $689M | $650M | $538M |
| EBITDA | $310M | $895M | -$71.1M | -$113M | -$311M |
| Net income | -$106M | $683M | -$363M | -$627M | -$559M |
| Free cash flow | $2.07M | $702M | -$114M | -$187M | -$389M |
| Capital expenditure | $51.8M | $300M | $74.2M | $121M | $152M |
| Total debt | $636M | $399M | $389M | $415M | $704M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| PTC Therapeutics PTCT | $5.47B | -11% | -35% | 22% | 34.8× | 8.0% |
| Sarepta Therapeutics SRPT | $1.88B | -11% | -20% | -3% | n/a | 11.9% |
| Roche RO.SW | $385B | +22% | -1% | 31% | 19.6× | 0.9% |
| Biogen BIIB | $36.7B | +28% | +2% | 17% | 16.8× | 9.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PTCT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.6% | +1.4% | 7th highest of 20 |
| 6-month return | -11.2% | -0.9% | 5th lowest of 19 |
| Distance from 52-week high | -28.0% | -27.9% | 10th lowest of 21 |
| Revenue growth (TTM) | -35.0% | +10.6% | lowest of 17 |
| Operating margin | 21.6% | 15.6% | 7th highest of 18 |
| Forward P/E | 34.8× | 24.0× | 4th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 8.0% | 7.8% | 8th least demanding of 15 |
| Growth delivered (Del g) | +35.4% | +9.8% | 3rd highest of 15 |
| Hurdle (Req g minus delivered) | -27.4 pp | -0.8 pp | 3rd least demanding of 15 |
| EV / EBITDA | 12.8× | 21.5× | 4th cheapest of 11 |
| Net debt / EBITDA | -4.8× | 0.7× | 2nd least indebted of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| PTC Therapeutics PTCT | United States | $5.47B | -11% | -35% | 22% | 34.8× | 8.0% | +35.4% |
| Supernus Pharmaceuticals SUPN | United States | $5.43B | -49% | +16% | 45% | 6.7× | 4.2% | +13.9% |
| Gland Pharma GLAND.NS | India | $5.53B | +69% | +18% | 20% | 39.0× | 28.0% | +13.3% |
| Apotex Health APTX.TO | Canada | $5.62B | n/a | +4% | 32% | 18.6× | -13.5% | +4.2% |
| Beijing TongRenTang 600085.SS | China | $5.27B | -8% | -17% | 8% | 31.2× | 2.7% | +6.2% |
| Sumitomo Pharma 4506.T | Japan | $5.23B | +7% | +11% | 10% | 8.3× | 1.4% | -2.6% |
| IPCA Laboratories IPCALAB.NS | India | $5.22B | +24% | +11% | 17% | 32.4× | 17.8% | +12.2% |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $5.18B | -39% | +14% | 11% | 41.6× | 15.5% | +9.7% |
| Veradermics MANE | United States | $5.80B | +31% | n/a | n/a | n/a | n/a | n/a |
| SKBP 326030.KS | South Korea | $5.12B | -11% | +39% | 35% | 21.6× | 0.5% | +93.6% |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.90B | -6% | +39% | 47% | 13.8× | 1.8% | +519.6% |
| Erasca ERAS | United States | $5.04B | +42% | n/a | n/a | n/a | n/a | n/a |
| Abbott India ABBOTINDIA.NS | India | $5.93B | -1% | +6% | 28% | 32.4× | 11.4% | +10.0% |
| Mirum Pharmaceuticals MIRM | United States | $6.12B | -13% | +42% | -21% | n/a | n/a | n/a |
| Ligand Pharmaceuticals LGND | United States | $6.12B | +38% | +1% | 14% | 28.0× | 57.8% | +7.5% |
| Belite Bio, Inc. ADR BLTE | United States | $6.20B | 0% | n/a | n/a | n/a | n/a | n/a |
| Novast Laboratories 301569.SZ | China | $4.82B | n/a | +3% | 27% | n/a | 42.6% | +3.1% |
| Travere Therapeutics TVTX | United States | $4.76B | +16% | +49% | -3% | 16.9× | 16.7% | +19.9% |
| Biocon BIOCON.NS | India | $6.28B | -4% | +6% | 8% | 56.4× | n/a | n/a |
| Humanwell Healthcare (Group) 600079.SS | China | $4.71B | +3% | -3% | 16% | 13.4× | -6.8% | +3.0% |
| Samsung Epis 0126Z0.KS | South Korea | $6.39B | -36% | n/a | -25% | 24.0× | n/a | n/a |